What is he best known for?
The fields of study he is best known for:
- Enzyme
- Internal medicine
- Cancer
His primary areas of investigation include Receptor, Signal transduction, Cell biology, Immunology and Thrombin.
His research in Receptor focuses on subjects like Platelet, which are connected to Pharmacology.
His Signal transduction study combines topics in areas such as Cell, Endocrinology and Internal medicine.
His Immunology research incorporates themes from Agonist and Matrix metalloproteinase.
His study in Thrombin is interdisciplinary in nature, drawing from both Biophysics, Protease and Biochemistry.
His study looks at the relationship between Protease-Activated Receptor 1 and topics such as Carcinogenesis, which overlap with Cancer cell and Cancer research.
His most cited work include:
- PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells (667 citations)
- PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells (667 citations)
- Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides (276 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Receptor, Pepducin, Pharmacology, G protein-coupled receptor and Platelet.
His Receptor research is multidisciplinary, relying on both Biophysics, Endocrinology and Cell biology.
His research in Pepducin intersects with topics in Cancer research, Immunology and Pathology.
The study incorporates disciplines such as Cancer cell, Breast cancer, Ovarian cancer and Protease-Activated Receptor 1 in addition to Cancer research.
His Immunology study integrates concerns from other disciplines, such as Matrix metalloproteinase and Stem cell.
Athan Kuliopulos's looking at G protein-coupled receptor as part of his Signal transduction and Biochemistry and G protein-coupled receptor study.
He most often published in these fields:
- Receptor (36.09%)
- Pepducin (27.07%)
- Pharmacology (27.82%)
What were the highlights of his more recent work (between 2013-2021)?
- Pharmacology (27.82%)
- Receptor (36.09%)
- Pepducin (27.07%)
In recent papers he was focusing on the following fields of study:
Athan Kuliopulos mostly deals with Pharmacology, Receptor, Pepducin, Platelet and Internal medicine.
Athan Kuliopulos interconnects Alanine transaminase, Alcoholic liver disease, Alcoholic hepatitis and Thrombin receptor in the investigation of issues within Pharmacology.
The various areas that he examines in his Receptor study include Inflammation, Ovarian cancer and Lung.
His biological study spans a wide range of topics, including Pharmacokinetics and Immunology, Neutrophilia, Hepatitis.
Athan Kuliopulos has included themes like Hemostasis, Thrombosis and GPR31 in his Platelet study.
Athan Kuliopulos combines subjects such as Endocrinology and Reductase with his study of Internal medicine.
Between 2013 and 2021, his most popular works were:
- Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease (60 citations)
- G-Protein–Coupled Receptors Signaling Pathways in New Antiplatelet Drug Development (45 citations)
- Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis (29 citations)
In his most recent research, the most cited papers focused on:
- Enzyme
- Internal medicine
- Cancer
Pharmacology, Biochemistry, Platelet, Cancer research and Thrombin are his primary areas of study.
In the field of Platelet, his study on Platelet aggregation inhibitor overlaps with subjects such as Ischaemic stroke.
His research in Cancer research intersects with topics in Cancer cell, Cancer, Metastatic breast cancer and Matrix metalloproteinase.
His Matrix metalloproteinase research includes themes of HEK 293 cells, Lung cancer, Knockout mouse and Immunology.
His Thromboxane A2 research entails a greater understanding of Receptor.
The concepts of his Receptor study are interwoven with issues in Biophysics and Signal transduction.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
